Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

William Blair initiated coverage of Upstream Bio with a rating of Outperform

TD Cowen initiated coverage of Upstream Bio with a rating of Buy

SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended Mar

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MATuesday, March 4, 2025, 11:50 a.m. – 12:20 p.m. ET Leerink Partners Global Biopharma Conference 2025, Miami FLWednesday, March 12, 2025, 1:40 p.m. – 2:10 p.m. ET A live webcast of the presentation will be available under the "Events" tab on the "Investors" page of the Company's website on the day of

Upstream's 2025 Automotive & Smart Mobility Cybersecurity Report reveals that 60% of cyber incidents could affect thousands to millions of connected vehicles, with massive-scale attacks more than tripling; the report emphasizes that current regulatory requirements are insufficient to address expanding cyber risks. ANN ARBOR, Mich., Feb. 11, 2025 /PRNewswire/ -- Upstream Security, the leading provider of cloud-based cybersecurity and data management platform purpose-built for automotive, smart mobility, and IoT ecosystem, today released the 2025 Automotive & Smart Mobility Cybersecurity Report. The annual report, returning for its seventh year, highlights that despite the increased regulatory

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio's CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 p.m. PT.   A live webcast of the presentation will be available under the "Events" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation. About Upstream Bio Upstream Bio is a clinical-stage biotechno

WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024.   Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against

WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio's CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET.  A live webcast of the presentation will be available under the "Events" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Upstream Bio Upstream Bio

– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the third quarter ended September 30, 2024, and provided a summary of recent business highlights.

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

3 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to